Once-weekly exenatide vs once- or twice-daily insulin detemir: randomised, open-label clinical trial of efficacy and safety in patients with Type 2 diabetes inadequately controlled with metformin alone or with sulphonylureas

被引：0
|
作者：
Davies, M. [1 ]
Heller, S. [2 ]
Sreenan, S. [3 ]
Sapin, H. [4 ]
Adetunji, O. [5 ]
Tahbaz, A. [5 ]
Vora, J. [6 ]
机构：
[1] Univ Leicester, Leicester, Leics, England
[2] Univ Sheffield, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England
[3] Connolly Hosp, Royal Coll Surg Ireland, Dublin, Ireland
[4] Lilly France, Suresnes, France
[5] Eli Lilly & Co, Basingstoke, Hants, England
[6] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
DIABETIC MEDICINE | 2013年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：57 / 58
页数：2
相关论文
共 50 条
  • [31] Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
    Pratley, Richard E.
    Nauck, Michael A.
    Barnett, Anthony H.
    Feinglos, Mark N.
    Ovalle, Fernando
    Harman-Boehm, Illana
    Ye, June
    Scott, Rhona
    Johnson, Susan
    Stewart, Murray
    Rosenstock, Julio
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (04): : 289 - 297
  • [32] Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
    Dungan, Kathleen M.
    Tofe Povedano, Santiago
    Forst, Thomas
    Gonzalez Gonzalez, Jose G.
    Atisso, Charles
    Sealls, Whitney
    Fahrbach, Jessie L.
    LANCET, 2014, 384 (9951): : 1349 - 1357
  • [33] Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
    Wysham, Carol H.
    Rosenstock, Julio
    Vetter, Marion L.
    Dong, Fang
    Ohman, Peter
    Iqbal, Nayyar
    DIABETES OBESITY & METABOLISM, 2018, 20 (01): : 165 - 172
  • [34] Impact of age on the efficacy and safety of once-weekly insulin icodec vs once-daily insulin in type 2 diabetes: ONWARDS 1-5
    Vianna, A. G. D.
    Desouza, C.
    Laugesen, C.
    Fragao-Marques, M.
    Nielsen, P. H.
    Shaikh, S.
    Lingvay, I.
    DIABETOLOGIA, 2024, 67 : S376 - S376
  • [35] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with Type 2 diabetes (SUSTAIN 4)
    Aroda, V. R.
    Bain, S. C.
    Cariou, B.
    Piletic, M.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    de Vries, J. H.
    DIABETIC MEDICINE, 2017, 34 : 146 - 146
  • [36] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    DeVries, J. H.
    Bain, S. C.
    Cariou, B.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    Aroda, V. R.
    DIABETOLOGIA, 2016, 59 : S76 - S77
  • [37] Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
    Gallwitz, Baptist
    Guzman, Juan
    Dotta, Francesco
    Guerci, Bruno
    Simo, Rafael
    Basson, Bruce R.
    Festa, Andreas
    Kiljanski, Jacek
    Sapin, Helene
    Trautmann, Michael
    Schernthaner, Guntram
    LANCET, 2012, 379 (9833): : 2270 - 2278
  • [38] Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
    McCrimmon, Rory J.
    Catarig, Andrei-Mircea
    Frias, Juan P.
    Lausvig, Nanna L.
    le Roux, Carel W.
    Thielke, Desiree
    Lingvay, Ildiko
    DIABETOLOGIA, 2020, 63 (03) : 473 - 485
  • [39] Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
    Rory J. McCrimmon
    Andrei-Mircea Catarig
    Juan P. Frias
    Nanna L. Lausvig
    Carel W. le Roux
    Desirée Thielke
    Ildiko Lingvay
    Diabetologia, 2020, 63 : 473 - 485
  • [40] Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
    Kaku, Kohei
    Yamada, Yuichiro
    Watada, Hirotaka
    Abiko, Atsuko
    Nishida, Tomoyuki
    Zacho, Jeppe
    Kiyosue, Arihiro
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1202 - 1212
12345